Ionis Pharmaceuticals Inc. Common Stock vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.24 (market cap $297.21M). The key difference: Ionis Pharmaceuticals Inc. Common Stock is far larger — about 23.7× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and YieldMax Magnificent 7 Fund of Option Income ETFs is more actively traded (809,569 versus 2,977,440). Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| IONS | YMAG | |
|---|---|---|
Market Cap | $7.04B | $297.21M |
Volume | 2,977,440 | 809,569 |
Sector | Health | Income / Options Overlay |
52-Week High | $86.50 | $15.68 |
52-Week Low | $42.38 | $10.76 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $6.60B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.55, up 0.7% today, with a neutral technical signal and bullish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. RSI levels show mixed signals with short-term overbought conditions. Support and resistance levels are tightly clustered around $11-$12, indicating potential for near-term consolidation.
The outlook remains balanced with high distribution yields providing income appeal, though technical indicators suggest limited near-term momentum. Key risks include NAV stability during earnings periods and dependency on underlying option strategies. Analyst coverage is limited, requiring careful monitoring of component fund performance and distribution sustainability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →